CAT
Caterpillar Inc.
CAT's fundamentals are strong, but it looks expensive: trading at 24x earnings, above its usual 18x. Analysts expect strong earnings growth, though they disagree widely on how much.
CSTE
Caesarstone Ltd.
There isn't enough reported data to score CSTE yet.
CAT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Strong |
CAT's revenue, profitability, cash flow and balance sheet are all currently healthy.
CSTE Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Under pressure | |
| Weak |
CSTE's revenue, profitability, cash flow and balance sheet are all currently under pressure.
CAT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 15x | $380 | -37% |
| Fair | 18x | $461 | -24% |
| Forward | 20x | $605 | — |
| Current | 24x | $605 | — |
| Expensive | 33x | $840 | +39% |
Historical ranges are pointers, not guarantees.
CAT's PE is in its expensive range at 24x. If earnings grow as analysts expect, today's price would be 20x next year's earnings, in its fair range.
CSTE PE Valuation
CSTE has no meaningful PE right now: it lost money over the past year.
CAT Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Moderate | |
| Low |
Analysts expect earnings and revenue growth for CAT, with profitability improving. However, they disagree widely on these estimates.
CSTE Forward outlook
There aren't enough analyst estimates for CSTE to show an outlook.
CAT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $29.73 | +17% |
| Q3 2026 | $25.48 | +31% |
| Q2 2026 | $23.23 | +18% |
| Q1 2026 | $20.08 | -2% |
| Q4 2025 | $18.81 | -15% |
| Q3 2025 | $19.46 | -9.7% |
| Q2 2025 | $19.64 | -10% |
| Q1 2025 | $20.50 | -7.4% |
| Q4 2024 | $22.05 | +9.6% |
CAT has the edge over CSTE on earnings quality, reporting a profit while its opponent remains loss making.
CSTE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$4.12 | -$2.49 |
| Q1 2026 | -$4.21 | -$2.85 |
| Q4 2025 | -$3.97 | -$2.83 |
| Q3 2025 | -$2.03 | -$0.03 |
| Q2 2025 | -$1.63 | +$0.28 |
| Q1 2025 | -$1.36 | +$1.80 |
| Q4 2024 | -$1.14 | +$1.98 |
| Q3 2024 | -$2.00 | +$1.80 |
CSTE lost $4.12 per share over the past year, a bigger loss than the year before.
CAT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $20.7B | +17% |
| Q2 2026 | $20.5B | +24% |
| Q1 2026 | $17.4B | +22% |
| Q4 2025 | $19.1B | +18% |
| Q3 2025 | $17.6B | +9.5% |
| Q2 2025 | $16.6B | -0.7% |
| Q1 2025 | $14.2B | -9.8% |
| Q4 2024 | $16.2B | -5% |
CAT has the edge over CSTE on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +3.1 points |
| Q2 2026 | 21% | +3.6 points |
| Q1 2026 | 18% | -0.4 points |
| Q4 2025 | 14% | -4.1 points |
| Q3 2025 | 17% | -2.2 points |
| Q2 2025 | 17% | -3.6 points |
| Q1 2025 | 18% | -4.2 points |
| Q4 2024 | 18% | -0.3 points |
CAT has the edge over CSTE on profitability, with a higher operating margin.
CSTE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $96.6M | -4.5% |
| Q1 2026 | $88.7M | -11% |
| Q4 2025 | $94.4M | -3.5% |
| Q3 2025 | $102.1M | -5.1% |
| Q2 2025 | $101.1M | -15% |
| Q1 2025 | $99.6M | -16% |
| Q4 2024 | $97.9M | -24% |
| Q3 2024 | $107.6M | -24% |
CSTE's revenue has slid since its 2022 peak: $97M last quarter, down 4.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -5.6% | +4.9 points |
| Q1 2026 | -12% | +2.7 points |
| Q4 2025 | -18% | +5 points |
| Q3 2025 | -16% | -12 points |
| Q2 2025 | -11% | -2.8 points |
| Q1 2025 | -15% | -10 points |
| Q4 2024 | -23% | +2.4 points |
| Q3 2024 | -3.8% | -2.4 points |
CSTE's operating margin was −5.6% last quarter, up 4.9 points from the same quarter a year ago.
CAT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $3.7B | +19% |
| Q2 2026 | $3.8B | +47% |
| Q1 2026 | $1.1B | +97% |
| Q4 2025 | $2.7B | +0.1% |
| Q3 2025 | $3.1B | -1.5% |
| Q2 2025 | $2.6B | -4.2% |
| Q1 2025 | $579M | -63% |
| Q4 2024 | $2.7B | -22% |
CAT has the edge over CSTE on cash generation, producing positive trailing cash flow while its opponent burns cash.
CSTE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $1.6M | +$15.1M |
| Q1 2026 | -$7.3M | +$9.4M |
| Q4 2025 | -$10.1M | -$4.9M |
| Q3 2025 | -$5.8M | -147% |
| Q2 2025 | -$13.5M | -261% |
| Q1 2025 | -$16.8M | -382% |
| Q4 2024 | -$5.2M | -148% |
| Q3 2024 | $12.4M | -48% |
CSTE has burned cash in six of the last eight quarters: −$22M over the past year, against −$23M the year before.
CAT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -1.6M shares |
| 1 year | -2.1% | -9.9M shares |
| 3 years | -10% | -51.7M shares |
| 5 years | -16% | -86.7M shares |
| Available history | -19% | -107M shares |
CAT has the edge over CSTE on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1.2B |
| Q2 2026 | $1.5B |
| Q1 2026 | $5B |
| Q4 2025 | $340M |
| Q3 2025 | $362M |
| Q2 2025 | $828M |
| Q1 2025 | $3.7B |
| Q4 2024 | $640M |
CAT spent $8.1B buying back its own shares over the past year, up 47% from the year before.
CSTE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +7.7K shares |
| 1 year | +0.1% | +24.9K shares |
| 3 years | +0.2% | +70.4K shares |
| 5 years | +0.1% | +44.9K shares |
| Available history | +0.4% | +142K shares |
CSTE has 35M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
CSTE hasn't bought back shares in the past year.
CAT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.5x | Net Cash |
| Q2 2026 | -0.4x | Net Cash |
| Q1 2026 | -0.3x | Net Cash |
| Q4 2025 | 2.0x | Healthy |
| Q3 2025 | -0.6x | Net Cash |
| Q2 2025 | -0.4x | Net Cash |
| Q1 2025 | -0.3x | Net Cash |
| Q4 2024 | 1.6x | Healthy |
CAT has more cash than debt.
CSTE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2023 | 24.9x | High |
| Q1 2023 | 2.6x | Moderate |
| Q4 2022 | 2.5x | Moderate |
| Q3 2022 | 1.9x | Healthy |
| Q2 2022 | 1.7x | Healthy |
| Q1 2022 | 1.8x | Healthy |
| Q4 2021 | 1.8x | Healthy |
| Q3 2021 | 1.0x | Healthy |
CSTE's net debt is more than 20 years of its operating earnings (EBITDA), up from 1.7 years a year ago.
CAT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.7 | Neutral |
| Stochastic | 6.7 | Oversold |
CAT's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
CSTE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.2 | Neutral |
| Stochastic | 4.9 | Oversold |
CSTE's weekly RSI is 35 (neutral) and its Stochastic is 5 (oversold).
CAT PE vs Industrials Sector
| Metric | CAT | Sector median | Relative |
|---|---|---|---|
| PE | 24x | 24x | 1.1% below |
| PE % | 69 | 58 | 11 pts above |
CAT is trading at 24x earnings, in line with the Industrials sector's median of 24x.
CSTE PE vs Industrials Sector
| Metric | CSTE | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 24x | — |
CSTE has no meaningful PE right now: it lost money over the past year.
CAT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $709.0 | 15% below |
| 20 week MA | $797.0 | 24% below |
| 50 week MA | $771.3 | 22% below |
| 100 week MA | $586.7 | 3.2% above |
| 200 week MA | $443.1 | 37% above |
CAT has the edge over CSTE on trend strength, trading above more of its moving averages.
CSTE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.21 | 41% below |
| 20 week MA | $2.51 | 48% below |
| 50 week MA | $2.00 | 35% below |
| 100 week MA | $2.19 | 41% below |
| 200 week MA | $3.47 | 63% below |
CSTE is in a downtrend: it's below all five of its weekly moving averages, and 63% below its 200-week average.
CAT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $148.3 | $179.6 | +21% |
| 2021 | $179.6 | $206.2 | +15% |
| 2022 | $206.2 | $239.9 | +16% |
| 2023 | $239.9 | $295.7 | +23% |
| 2024 | $295.7 | $364.9 | +23% |
| 2025 | $364.9 | $583.0 | +60% |
| 2026 YTD | $583.0 | $605.3 | +3.8% |
CAT has the edge over CSTE on returns for 2026, with the stronger performance.
CSTE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $14.9 | $11.0 | -26% |
| 2021 | $11.0 | $11.2 | +2.4% |
| 2022 | $11.2 | $5.83 | -48% |
| 2023 | $5.83 | $3.74 | -36% |
| 2024 | $3.74 | $4.42 | +18% |
| 2025 | $4.42 | $1.71 | -61% |
| 2026 YTD | $1.71 | $1.30 | -24% |
CSTE has finished lower in four of the last six years. It's down 24% so far in 2026.